Literature DB >> 12040022

Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system.

Karl D Whitney1, Michael A Watson, Jon L Collins, William G Benson, Tammy M Stone, Mary Jo Numerick, Timothy K Tippin, Joan G Wilson, Deborah A Winegar, Steven A Kliewer.   

Abstract

The nuclear oxysterol receptors liver X receptor-alpha [LXRalpha (NR1H3)] and LXRbeta (NR1H2) coordinately regulate genes involved in cholesterol homeostasis. Although both LXR subtypes are expressed in the brain, their roles in this tissue remain largely unexplored. In this report, we show that LXR agonists have marked effects on gene expression in murine brain tissue both in vitro and in vivo. In primary astrocyte cultures, LXR agonists regulated several established LXR target genes, including ATP binding cassette transporter A1, and enhanced cholesterol efflux. In contrast, little or no effect on gene expression or cholesterol efflux was detected in primary neuronal cultures. Treatment of mice with a selective LXR agonist resulted in the induction of several LXR target genes related to cholesterol homeostasis in the cerebellum and hippocampus. These data provide the first evidence that the LXRs regulate cholesterol homeostasis in the central nervous system. Because dysregulation of cholesterol balance is implicated in central nervous system diseases such as Alzheimer's and Niemann-Pick disease, pharmacological manipulation of the LXRs may prove beneficial in the treatment of these disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12040022     DOI: 10.1210/mend.16.6.0835

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  63 in total

1.  Transcritpional effects of S100B on neuroblastoma cells: perturbation of cholesterol homeostasis and interference on the cell cycle.

Authors:  C Bernardini; W Lattanzi; R Businaro; S Leone; V Corvino; G Sorci; G Lauro; L Fumagalli; F R Donato; F Michetti
Journal:  Gene Expr       Date:  2010

2.  Hydroxysteroid sulfotransferase 2B1b expression and localization in normal human brain.

Authors:  Emily D Salman; Ona Faye-Petersen; Charles N Falany
Journal:  Horm Mol Biol Clin Investig       Date:  2011-10

Review 3.  Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.

Authors:  Miguel Moutinho; Gary E Landreth
Journal:  J Lipid Res       Date:  2017-03-06       Impact factor: 5.922

Review 4.  The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration.

Authors:  Radosveta Koldamova; Nicholas F Fitz; Iliya Lefterov
Journal:  Biochim Biophys Acta       Date:  2010-02-24

Review 5.  Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease.

Authors:  Nicholas F Fitz; Kyong Nyon Nam; Radosveta Koldamova; Iliya Lefterov
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

Review 6.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

7.  24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury.

Authors:  Casandra M Cartagena; Mark P Burns; G William Rebeck
Journal:  Brain Res       Date:  2010-01-04       Impact factor: 3.252

8.  Increased expression of RXRα in dementia: an early harbinger for the cholesterol dyshomeostasis?

Authors:  Afia Akram; James Schmeidler; Pavel Katsel; Patrick R Hof; Vahram Haroutunian
Journal:  Mol Neurodegener       Date:  2010-09-15       Impact factor: 14.195

9.  Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-β peptides in the cerebral spinal fluid of rats.

Authors:  Sokreine Suon; Jie Zhao; Stephanie A Villarreal; Nikesh Anumula; Mali Liu; Linda M Carangia; John J Renger; Celina V Zerbinatti
Journal:  Mol Neurodegener       Date:  2010-10-29       Impact factor: 14.195

10.  Treatment with LXR agonists after focal cerebral ischemia prevents brain damage.

Authors:  Luigi Sironi; Nico Mitro; Mauro Cimino; Paolo Gelosa; Uliano Guerrini; Elena Tremoli; Enrique Saez
Journal:  FEBS Lett       Date:  2008-09-19       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.